Seer, Inc. (SEER) Stock Price & Analysis
Seer, Inc. (SEER) fell 5.59% to USD 1.69 as of June 10, 2026 at 00:42 UTC, according to Nexqual real-time market data.
SEER last closed at USD 1.79; the session ranged USD 1.69–1.79 on volume of 436,657 shares. Market capitalization is $92.92M, with a 52-week range of USD 1.65–2.41 (NMS). Source: Nexqual, June 10, 2026 at 00:42 UTC.
Key Statistics (as of June 10, 2026 at 00:42 UTC)
| Price | USD 1.69 |
|---|---|
| Change | ▼ 5.59% (down) |
| Previous Close | USD 1.79 |
| Open | USD 1.79 |
| Day Range | USD 1.69 – 1.79 |
| 52-Week Range | USD 1.65 – 2.41 |
| Volume | 436,657 shares |
| Market Cap | $92.92M |
| Exchange | NMS |
Technical Analysis (SEER)
Nexqual's technical model rates SEER "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:42 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.75 (neutral) |
| vs SMA50 | Below (USD 1.84) |
| MACD | -0.01 (negative) |
Analyst Ratings (SEER)
Wall Street analysts rate SEER "None" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of June 10, 2026 at 00:42 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4 |
| High Target | USD 4 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (SEER)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.27 |
| Revenue Estimate | $3.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.3 vs est -0.3 ▼ miss |
| 2025-12-31 | USD -0.29 vs est -0.32 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.3 ▼ miss |
| 2025-06-30 | USD -0.33 vs est -0.37 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financials & Fundamentals (SEER)
| Total Revenue | $15.17M |
|---|---|
| Revenue Growth (YoY) | -33.60% |
| Gross Margin | +48.70% |
| Operating Margin | -617.83% |
| Profit Margin | +0.00% |
| ROE | -25.52% |
| Debt / Equity | 9.54 |
| Current Ratio | 17.73 |
| Total Cash | $166.67M |
| Total Debt | $23.03M |
| Free Cash Flow | $-31.68M |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financial Health Score (SEER)
Nexqual rates Seer, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:42 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $167M cash vs $23M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$32M, burning cash |
| Efficiency | Critical — ROE -26%, ROA -15.0% |
Ownership (SEER)
| Insider Ownership | +14.47% |
|---|---|
| Institutional Ownership | +51.16% |
| Shares Outstanding | 54.98M |
| Float | 40.11M |
| Short % of Float | +0.60% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Leadership (SEER)
Seer, Inc. is led by Omid C. Farokhzad (age 56), Founder, CEO, & Chair of the Board of Directors, per Nexqual as of June 10, 2026 at 00:42 UTC.
| Founder, CEO, & Chair of the Board of Directors | Omid C. Farokhzad (age 56) |
|---|---|
| President,Treasurer & CFO | David R. Horn (age 57) |
| Senior Vice President of Product Development | Martin Goldberg |
| Senior Vice President of Research & Tech Development | Asim Siddiqui |
Major Backers & Investors (SEER)
Notable institutional backers of Seer, Inc. include Softbank Group Corporation, Siren, L.L.C., Acadian Asset Management. LLC, according to Nexqual as of June 10, 2026 at 00:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Softbank Group Corporation | 9.28% |
| Siren, L.L.C. | 4.44% |
| Acadian Asset Management. LLC | 3.75% |
| Renaissance Technologies | 1.77% |
| Nano Cap New Millennium Growth Fund L P | 1.49% |
| AJU IB Investment Company Limited | 1.48% |
| Two Sigma Investments, LP | 0.92% |
| Bridgeway Capital Management, LLC | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.01% |
| BlackRock | 4.04% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
From Seer, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa.
- The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
- The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution.
- It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCAB | BioAtla, Inc. | USD 3.44 | ▲ 3.3% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.94 | ▲ 3.41% |
| MASS | 908 Devices Inc. | USD 7.99 | ▲ 0.76% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
| CERT | Certara, Inc. | USD 5.18 | ▼ 3.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:42 UTC. This page is informational and not investment advice.